Year: 2016
Language: Arabic
Author(s): World Federation of Hemophilia
Format: Document
This resource has also been translated into the following languages, with permission from the WFH, by NMOs: Polish
Desmopressin (DDAVP) may be the treatment of choice for patients with mild or moderate hemophilia A and type 1 von Willebrand disease (VWD). This Fact Sheet presents essential information about this synthetic medicine which costs much less than plasma products or recombinant clotting factor concentrates, carries no risk of transmission of viral infections, and is on the World Health Organization’s (WHO) Model List of Essential Medicines (EML).
Listen to this 90-minute webinar presented on March 8, 2022, to learn about women and girls with bleeding disorders. The
Listen to this 90-minute webinar presented on September 1, 2021 to learn about advocating for better care using the ASH
Listen to this 2-hour webinar presented on December 16, 2021, to learn about global topics related to bleeding disorders, with
Listen to this 90-minute webinar, Strengthening comprehensive care: using data to inform clinical practice, presented on November 11, 2021. This
Listen to this 90-minute webinar presented on October 29, 2021 on Communicating impact: tips on effective reporting. This webinar offers
VWD Diagnosis Guidelines Executive Summary VWD Management Guidelines Executive Summary These clinical practice guidelines for the diagnosis and management of
